Other

2028

Merck & Co. 2028 increased by 56.5% to $3.60B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 56.5%, from $2.30B to $3.60B. Over 5 years (FY 2020 to FY 2025), 2028 shows an upward trend with a 19.1% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.

Analysis

StatementBalance Sheet Statement
SectionOther
CategoryProfitability
SignalLower is better
VolatilityStable
First reportedQ4 2015
Last reportedQ4 2025Feb 24, 2026

How to read this metric

A declining trend in these annual projections indicates that the bank's historical acquisition costs are being successfully absorbed.

Detailed definition

This represents the projected amortization expense for finite-lived intangible assets for the year 2028. It reflects the...

Peer comparison

Standard disclosure for banks with significant historical acquisition activity.

Metric ID: other_finite_lived_intangible_assets_amortization_expens_398565

Historical Data

5 periods
 Q4 '21Q4 '22Q4 '23Q4 '24Q4 '25
Value$1.60B$1.70B$1.70B$2.30B$3.60B
QoQ Change+6.3%+0.0%+35.3%+56.5%
YoY Change+6.3%+0.0%+35.3%+56.5%
Range$1.60B$3.60B
CAGR+125.0%
Avg YoY Growth+24.5%
Median YoY Growth+20.8%
Current Streak4+ quarters growth

Frequently Asked Questions

What is Merck & Co.'s 2028?
Merck & Co. (MRK) reported 2028 of $3.60B in Q4 2025.
How has Merck & Co.'s 2028 changed year-over-year?
Merck & Co.'s 2028 increased by 56.5% year-over-year, from $2.30B to $3.60B.
What is the long-term trend for Merck & Co.'s 2028?
Over 5 years (2020 to 2025), Merck & Co.'s 2028 has grown at a 19.1% compound annual growth rate (CAGR), from $1.50B to $3.60B.
What does 2028 mean?
The expected non-cash expense for acquired intangible assets in the year 2028.